Bio-Techne Corporation (TECH) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Minneapolis, MN, United States. El CEO actual es Kim Kelderman.
TECH tiene fecha de IPO 1989-02-09, 3,100 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $9.18B.
Bio-Techne Corporation is a life sciences company that develops, manufactures, and sells reagents, instruments, and diagnostic services for research and clinical markets globally. Operating through two main segments—Protein Sciences and Diagnostics and Genomics—the company offers a comprehensive portfolio including biological reagents, antibodies, cytokines, proteomic analytical tools, and diagnostic assays for oncology, genetic screening, and molecular diagnostics. Its products serve cell and gene therapy, tissue analysis, and hematology applications under recognized brands including R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, and Asuragen. Founded in 1976 and headquartered in Minneapolis, Minnesota, Bio-Techne has established itself as a trusted supplier to academic institutions, pharmaceutical companies, clinical laboratories, and diagnostic centers worldwide.
